Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor

Blood

Volumn 116, Issue 2, 2010, Pages 280-286

  Flood, Veronica H ^a,b   Gill, Joan Cox ^a,b,c   Morateck, Patricia A ^c   Christopherson, Pamela A ^c   Friedman, Kenneth D ^c   Haberichter, Sandra L ^a,b,c   Branchford, Brian R ^a   Hoffmann, Raymond G ^a   Abshire, Thomas C ^d   Di Paola, Jorge A ^e   Hoots, W Keith ^f   Leissinger, Cindy ^g   Lusher, Jeanne M ^h   Ragni, Margaret V ⁱ   Shapiro, Amy D ^j   Montgomery, Robert R ^a,b,c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^c BLOOD RESEARCH INSTITUTE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

^j INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN IB; RISTOCETIN; VON WILLEBRAND FACTOR; BOTROCETIN; DIAGNOSTIC AGENT; SNAKE VENOM;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; ETHNIC DIFFERENCE; EXON; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; SINGLE NUCLEOTIDE POLYMORPHISM; VON WILLEBRAND DISEASE; BLOOD CLOTTING PARAMETERS; GENETICS; METABOLISM; METHODOLOGY; POLYMERASE CHAIN REACTION;

AFRICAN AMERICANS; CROTALID VENOMS; EXONS; HUMANS; PLATELET FUNCTION TESTS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISTOCETIN; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 77955499972     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-249102     Document Type: Article

References (41)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69(2):454-459.
2. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84(2):160-174.
3. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
4. Tosetto A, Rodeghiero F, Castaman G, et al. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost. 2007;5(4):715-721.
5. Kitchen S, Jennings I, Woods TA, Kitchen DP, Walker ID, Preston FE. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost. 2006;32(5):492-498.
6. Meijer P, Haverkate F.An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost. 2006;32(5):485-491.
7. Favaloro EJ.An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost. 2007;33(8):727-744.
8. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691-1695.
9. James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood. 2007;109(1):145-154. (Pubitemid 46053055)
10. Miller CH, Dilley A, Richardson L, Hooper WC, Evatt BL. Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women. Am J Hematol. 2001;67(2):125-129.
11. Miller CH, Haff E, Platt SJ, et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost. 2003;1(10):2191-2197.
12. Fujimura Y, Titani K, Holland LZ, et al. von Willebrand factor: a reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem. 1986;261(1):381-385.
13. Gralnick HR, Williams S, McKeown L, et al. A monomeric von Willebrand factor fragment, Leu-504-Lys-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX [corrected]. Proc Natl Acad Sci U S A. 1992;89(17):7880-7884.
14. Rabinowitz I, Tuley EA, Mancuso DJ, et al. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Proc NatlAcad Sci U S A. 1992;89(20):9846-9849.
15. Mancuso DJ, Kroner PA, Christopherson PA, Vokac EA, Gill JC, Montgomery RR. Type 2M: Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets. Blood. 1996;88(7):2559-2568.
16. Hillery CA, Mancuso DJ, Evan Sadler J, et al. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets. Blood. 1998;91(5):1572-1581.
17. International Society on Thrombosis and Haemostasis Scientific and Standardization Committee. ISTH-SSC VWF Online Database. http://www.vwf.group. shef.ac.uk. Accessed February 15, 2010.
18. Branchford BR, Gill JC, Flood VH, et al. Racial disparity in the diagnosis of von Willebrand disease (VWD) with particular reference to the diagnosis of type 2M VWD in African Americans. Paper presented at Annual Meeting of the Pediatric Academic Society, Toronto, ON, May 6, 2007.
19. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4(4):766-773.
20. Montgomery RR, Hathaway WE, Johnson J, Jacobson L, Muntean W. A variant of von Willebrand's disease with abnormal expression of factor VIII procoagulant activity. Blood. 1982;60(1):201-207.
21. Flood VH, Friedman KD, Gill JC, et al. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost. 2009;7(11):1832-1839.
22. Pareti FI, Niiya K, McPherson JM, Ruggeri ZM. Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. J Biol Chem. 1987;262(28):13835-13841.
23. Eikenboom J, Van Marion V, Putter H, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost. 2006;4(4):774-782.
24. Federici AB. Diagnosis of inherited von Willebrand disease: a clinical perspective. Semin Thromb Hemost. 2006;32(6):555-565.
25. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171-232.
26. Szanto T, Schlammadinger A, Staelens S, et al. The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein Ibalpha. Thromb Haemost. 2007;98(1):178-185.
27. Buchanan GR, Holtkamp CA, Levy EN. Racial differences in ristocetin-induced platelet aggregation. Br J Haematol. 1981;49(3):455-464.
28. Mackie I, Bull H, Kennedy J, Brozovic M. Ristocetin-induced platelet agglutination in Afro-Caribbean and Caucasian people. Br J Haematol. 1982;50(1):171-173. (Pubitemid 12168678)
29. Philipp CS, Dilley A, Miller CH, et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost. 2003;1(3):477-484.
30. Cruz MA, Yuan H, Lee JR, Wise RJ, Handin RI. Interaction of the von Willebrand factor (vWF) with collagen: localization of the primary collagen-binding site by analysis of recombinant vWF a domain polypeptides. J Biol Chem. 1995;270(18):10822-10827.
31. Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem. 1991;266(13):8149-8155.
32. Gangarosa EJ, Landerman NS, Rosch PJ, Herndon EG Jr. Hematologic complications arising during ristocetin therapy: relation between dose and toxicity. N Engl J Med. 1958;259(4):156-161.
33. Howard MA, Sawers RJ, Firkin BG. Ristocetin: a means of differentiating von Willebrand's disease into two groups. Blood. 1973;41(5):687-690.
34. Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation: relationship to factor VIII procoagulant activity and antigen content. J Clin Invest. 1973;52(11):2708-2716.
35. Coller BS. The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility. J Clin Invest. 1978;61(5):1168-1175.
36. Huizinga EG, Tsuji S, Romijn RA, et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002;297(5584):1176-1179.
37. Mohri H, Fujimura Y, Shima M, et al. Structure of the von Willebrand factor domain interacting with glycoprotein Ib. J Biol Chem. 1988;263(34):17901-17904.
38. Girma JP, Takahashi Y, Yoshioka A, Diaz J, Meyer D. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib. Thromb Haemost. 1990;64(2):326-332.
39. De Luca M, Facey DA, Favaloro EJ, et al. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation. Blood. 2000;95(1):164-172.
40. Weiss HJ, Sussman II. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers. Blood. 1986;68(1):149-156.
41. Holmberg L, Dent JA, Schneppenheim R, Budde U, Ware J, Ruggeri ZM. von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure. J Clin Invest. 1993;91(5):2169-2177.